Development of Graves' Ophthalmopathy after Radioactive Iodine Ablation Using Recombinant Human Thyrotropin for Incidentally Discovered Papillary Thyroid Carcinoma.
10.11106/ijt.2017.10.2.102
- Author:
Ji Sun PARK
1
Author Information
1. Department of Nuclear Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea. nmdsun@naver.com
- Publication Type:Case Report
- Keywords:
Graves' ophthalmopathy;
Thyroid cancer;
Recombinant human thyrotropin;
Radioactive iodine
- MeSH:
Adult;
Eyelids;
Female;
Graves Disease;
Humans*;
Iodine*;
Thyroid Gland*;
Thyroid Neoplasms*;
Thyroidectomy;
Thyrotropin*
- From:International Journal of Thyroidology
2017;10(2):102-106
- CountryRepublic of Korea
- Language:English
-
Abstract:
Several studies have revealed an association between radioactive iodine (RAI) therapy for Graves' disease and new or worsening Graves' ophthalmopathy. In the present case, thyroid papillary cancer was incidentally detected in a 43-year-old woman who was receiving medication for Graves' disease. This patient had undergone RAI ablation using recombinant human thyrotropin (rhTSH) after total thyroidectomy. The patient subsequently complained of a unilateral eyelid abnormality at approximately 6 months after the RAI ablation, and was diagnosed with bilateral Graves' ophthalmopathy after a thorough ophthalmological examination. I report this case for its interesting clinical features, rarity of occurrence and to highlight the importance of careful observation for appropriate management of Graves' ophthalmopathy developing or worsening after RAI ablation in differentiated thyroid cancer patients.
